Blood News and Research

RSS

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Positive results from Cook Medical's REFORM stent clinical trial for treatment of renal artery stenosis

Study investigators today reported initial data from Cook Medical's REFORM clinical trial that is aimed at assessing the safety and effectiveness of the company's balloon-expandable renal stent for the treatment of renal artery stenosis. The data, presented by Robert Bersin, M.D., at ISET 2011, reveal a nine-month primary patency rate of 89.5 percent and a 97 percent rate of successful delivery and deployment of the stent.

18 Jan 2011

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Biological Psychiatry is proud to announce this week's publication of a special issue focusing on postmortem studies of psychosis. This special issue showcases the use of human brains postmortem to study psychiatric disorders, focusing on schizophrenia. The review articles highlight the benefits, achievements, problems, and perhaps most importantly, the future of postmortem research.

18 Jan 2011

Critical Diagnostics' Presage ST2 Assay effectively risk-stratifies chronic heart failure patients

Critical Diagnostics, the exclusive developer of the Presage® ST2 Assay, announces the publication of the Penn Heart Failure Study (PHFS) in an advance e-publication of the January 19, 2010 edition of Circulation: Heart Failure. The results of this study demonstrated that ST2 levels not only predict outcomes for ambulatory outpatients with chronic heart failure, they more effectively risk-stratify such patients.

18 Jan 2011

Quebec reimburses VIDAZA for treatment of blood cancer

Quebec patients with serious blood cancers (intermediate-2 and high-risk myelodysplastic syndrome and acute myeloid leukemia) now have publicly funded access to a new innovative therapy, VIDAZA® (azacitidine). Following a priority review and subsequent positive recommendation from the Conseil du medicament, patients now have the potential to significantly extend survival.

18 Jan 2011

Seordus recieves Japanese patent for SER100

The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.

18 Jan 2011

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

A new guideline from the American Academy of Neurology recommends using plasma exchange to treat people with severe relapses in multiple sclerosis and related diseases, as well as those with certain kinds of nerve disorders known as neuropathies.

18 Jan 2011

Drug-coated stents hold promise for treatment of clogged leg arteries

Drug-coated stents hold promise as a safe and lasting solution for the treatment of clogged leg arteries, suggest two-year results of the Zilver PTX Trial being presented at the 23rd annual International Symposium on Endovascular Therapy (ISET). Blocked leg arteries are a symptom of peripheral arterial disease (PAD), which affects 8 to 12 million Americans.

18 Jan 2011

'Master switch' protein in white blood cells linked to inflammation

Scientists have identified a protein that acts as a "master switch" in certain white blood cells, determining whether they promote or inhibit inflammation. The study, published in the journal Nature Immunology, could help researchers look for new treatments for diseases such as rheumatoid arthritis that involve excessive inflammation.

18 Jan 2011

Bathing tumor-ridden livers in chemotherapy increases survival time

Bathing tumor-ridden livers in chemotherapy increases the length of time certain cancer patients survive without progression of the disease, according to Phase III trial results being presented at the 3rd annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).

18 Jan 2011

RTS,S offers 46 percent protection against malaria for at least 15 months after vaccination, Study finds

A Phase II trial published Friday in Lancet Infectious Diseases has shown that RTS,S, the "experimental malaria vaccine from GlaxoSmithKline provides African children with long-lasting protection" against malaria, Reuters reports.

18 Jan 2011

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

Two multinational clinical studies indicate that the RDI’s system for predicting how HIV and AIDS patients will respond to different drugs could be a useful tool with potential clinical and economic benefits. The studies, published in the January issue of AIDS Patient Care and STDs, involved highly experienced physicians in the USA, Canada and Italy who used the system to help them select the optimum combination of HIV drugs for patients whose therapy was failing.

18 Jan 2011

Research finds resistance training results in 20% decrease in person's blood pressure

Research conducted in the College of Health Sciences' Department of Health, Leisure and Exercise Science at Appalachian State University has shown that resistance training has some similar effects as aerobic exercise in lowering a person's blood pressure.

18 Jan 2011

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Regeneron and Bayer HealthCare announced initiation of a new Phase 3 clinical trial in collaboration with the Singapore Eye Research Institute investigating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia.

18 Jan 2011

Polysomnography may predict adverse outcomes following pediatric adenotonsillectomy: Study

Performing polysomnography prior to pediatric adenotonsillectomy may help identify children at a higher risk of developing postoperative respiratory complications, according to a report in the January issue of Archives of Otolaryngology - Head Neck Surgery, one of the JAMA/Archives journals.

18 Jan 2011

Blood News and Research

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

Positive results from Cook Medical's REFORM stent clinical trial for treatment of renal artery stenosis

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Critical Diagnostics' Presage ST2 Assay effectively risk-stratifies chronic heart failure patients

Quebec reimburses VIDAZA for treatment of blood cancer

Seordus recieves Japanese patent for SER100

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

Drug-coated stents hold promise for treatment of clogged leg arteries

'Master switch' protein in white blood cells linked to inflammation

Bathing tumor-ridden livers in chemotherapy increases survival time

RTS,S offers 46 percent protection against malaria for at least 15 months after vaccination, Study finds

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

Research finds resistance training results in 20% decrease in person's blood pressure

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Polysomnography may predict adverse outcomes following pediatric adenotonsillectomy: Study

Antibiotics with blood pressure medications may cause hypotension

Study reports warfarin users may face risk of death after traumatic injuries

Eating less during early pregnancy impairs fetal brain development: Study

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

New magnetic pill system can serve as drug delivery tool in patients with cancer, diabetes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News